Lung Cancer Screening: Radiologic and Clinical Implications. Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill
|
|
|
- Domenic McKenzie
- 6 years ago
- Views:
Transcription
1 Lung Cancer Screening: Radiologic and Clinical Implications Katherine R. Birchard, M.D. University of North Carolina at Chapel Hill
2
3 Nothing to disclose
4 Objectives In context of NLST: Review Imaging Techniques Review Current Data on Radiation Doses from medical imaging Review Appearances of False Positives Review Pathology that may cause Overdiagnosis
5 A Brief History Many Randomized and non-randomized controlled trials over the years: 1970 s: Trials with Sputum Culture and Chest xray Mayo CT Screening Study No control arm (model as control arm) ELCAP Study Large! 65,000 pts; No control arm DANTE Trial- Small nos., LDCT and control = same
6 A Brief History In many studies, groups that were intervened upon had/were found to have: More lung cancers More early stage lung cancers More resectable lung cancers But! No significant reduction in lung cancer mortality, especially compared to overall mortality (Mayo) Enter the NLST
7 The National Lung Screening Trial 53,454 patients, 55-74, 30 pack-years, quit 15 years ago 26,722 LDCT; 26,732 Chest X-ray Three annual exams, median follow-up time = 6.4 years
8 -Larke et al, Kruger R et al; ACRIN-NLST Sessions, RSNA Gatsonis C et al, NLST: Overview and Study Design. Radiol Jan 2011; 258: The National Lung Screening Trial Chest X-Ray Technique: Single PA Film
9
10
11 -Larke et al, Kruger R et al; ACRIN-NLST Sessions, RSNA Gatsonis C et al, NLST: Overview and Study Design. Radiol Jan 2011; 258: The National Lung Screening Trial Chest X-Ray Technique: Single PA Film Median effective dose = msv; (95 th percentile = msv; 5 th percentile = msv) Context: US citizen average effective dose = 3mSv/year 1/100 of the dose
12 -Larke et al, Kruger R et al; ACRIN-NLST Sessions, RSNA Gatsonis C et al, NLST: Overview and Study Design. Radiol Jan 2011; 258: The National Lung Screening Trial CT Technique: Non-contrast, helical
13
14
15 -Larke et al, Kruger R et al; ACRIN-NLST Sessions, RSNA Gatsonis C et al, NLST: Overview and Study Design. Radiol Jan 2011; 258: The National Lung Screening Trial CT Technique: Non-contrast, helical Standardization across sites quite complicated
16
17 -Larke et al, Kruger R et al; ACRIN-NLST Sessions, RSNA Gatsonis C et al, NLST: Overview and Study Design. Radiol Jan 2011; 258: The National Lung Screening Trial CT Technique: Non-contrast, helical Standardization quite complicated Average effective dose of NLST CT scan = 1.4 msv Context: US citizen average effective dose = 3mSv/year 1/2 of the dose
18 The National Lung Screening Trial: Early Results LDCT group had more detected cancers and more early stage cancers than X-ray group We are not so surprised
19
20
21
22
23 The National Lung Screening Trial: Early Results LDCT group had more detected cancers and more early stage cancers than X-ray group We are not so surprised Significant reduction in lung cancer mortality announced in November 2010 by NCI
24 NLST, NEJM Aug ;5: National Lung Screening Trial: Abstract Data LDCT Chest X-Ray 247 lung cancer deaths per 100,000 person-yrs 309 lung cancer deaths per 100,000 person-yrs -20% relative reduction in mortality from lung cancer in LDCT group compared to Chest X-ray group (95CI, p=0.004) -6.7% fewer deaths from any cause in LDCT group compared to Chest X-ray group (95CI, p=0.02)
25 National Lung Screening Trial: The Numbers LDCT Deaths X-Ray Deaths Lung Cancer: 427* Cardiovascular: 486 *Difference of 76 = 15% Lung Cancer: 503* Cardiovascular: 470 Respiratory Illness: 175 Respiratory Illness: 226 Complic. Med/Surg: 12 For Lung Cancer Complic. Med/Surg: 7 Other: 349 Other: 343 Unknown: 12 Total Deaths: 1865 Not included * Difference of 121 = 6.1% Unknown: 7 Total Deaths: 1998 (NLST, NEJM Aug ;5: )
26 (NLST, NEJM Aug ;5:39 National Lung Screening Trial: False Positives LDCT Chest X-Ray False Positives: 96.4% False Positives: 94.5%
27
28
29
30
31
32 National Lung Screening Trial: Overdiagnosis LDCT Chest X-Ray BAC Stage 1A = 83 BAC Stage 1A = 17
33
34 National Lung Screening Trial Lung cancer screening: not ready for primetime Why? False Positives risks outweigh benefits? Overall mortality needs to be further investigated Must assess impact/meaning of overdiagnosis further Must assess morbidity associated with screening, as well as emotional burden on patients Determine Cost and who will pay Probably okay on radiation front
35 Effective Doses of Common Exams: Procedure Effective dose (msv) PA chest radiograph CT Head 2.0 Lumbar Spine radiograph 1.5 Bone Scan (Nuclear) 6.3 Chest CT 5-7 Abdomen CT 6-8 Chest CTA 8-15 Cardiac catheterization 8-17
36 More on Radiation Brenner DJ, et al. Computed Tomography-An Increasing Source of Radiation Brenner Exposure. DJ et NEJM al. New 2007; Eng 357: J Med 2006
37 Lung Cancer Screening Where do we go from here? Use current guidelines for abnormalities detected on CT
38 Current Guidelines MacMahon H et al. Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society Radiol 2005
39 Lung Cancer Screening Where do we go from here? Use current guidelines for abnormalities detected on CT Await NELSON Trial results, ItalaLUNG Trial
40 Conclusions: In context of NLST: Reviewed Imaging Techniques Reviewed Current Data on Radiation Doses from medical imaging Reviewed Appearances of False Positives Reviewed Pathology that may be cause Overdiagnosis
41 Thank you for your attention!
Lung Cancer Screening: To Screen or Not to Screen?
Lung Cancer Screening: To Screen or Not to Screen? Lorriana Leard, MD Co-Director of UCSF Lung Cancer Screening Program Vice Chief of Clinical Activities UCSF Pulmonary, Critical Care, Allergy & Sleep
A Comprehensive Cancer Center Designated by the National Cancer Institute
N C I C C C A Comprehensive Cancer Center Designated by the National Cancer Institute Screening and Early Detection of Lung Cancer: Ready for Practice? David S. Ettinger, MD, FACP, FCCP Alex Grass Professor
Lung Cancer Screening: To screen or not to screen?
Lung Cancer Screening: To screen or not to screen? Dan J. Raz, M.D. Co Director, Lung Cancer Screening Program Co Director, LungCancer and Thoracic OncologyProgram Assistant Professor, Thoracic Surgery
Pulmonary Nodules. Michael Morris, MD
Pulmonary Nodules Michael Morris, MD Case 45 year old healthy male Smokes socially Normal physical exam Pre-employment screening remote +PPD screening CXR nodular opacity Case 45 year old healthy male
Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center
You Smoke, You Get Lung Cancer, You Die: Can Screening Change this Paradigm? Robert J. McKenna M.D. Chief, Thoracic Surgery Cedars Sinai Medical Center AATS Saturday 4/28/2012 Cancer Screening Cancer
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University
LUNG CANCER SCREENING WHAT S THE IMPACT? Nitra Piyavisetpat, MD Department of Radiology Chulalongkorn University Objective LDCT lung cancer screening (LCS) Potential Benefits & Harms Recommendation of
Lung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
Will CT screening reduce overall lung cancer mortality? Associate Professor of Radiology Department of Medical Imaging UHN / MSH / WCH
Will CT screening reduce overall lung cancer mortality? Heidi Roberts MD FRCP(C) Heidi Roberts, MD, FRCP(C) Associate Professor of Radiology Department of Medical Imaging UHN / MSH / WCH Screening - Requirements
Lung Cancer Screening Trials. Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital
Lung Cancer Screening Trials Edward Harris Respiratory Research Fellow Sir Charles Gairdner Hospital Lung Cancer Screening in Australia Not Funded except as part of a clinical trial Rationale PLCO, ELCAP
Christine Argento, MD Interventional Pulmonology Emory University
Christine Argento, MD Interventional Pulmonology Emory University Outline Lung Cancer Statistics Prior Studies for Lung Cancer Screening NLST Studies Following NLST Future Directions Lung Cancer American
Goals of Presentation
Goals of Presentation Review context of lung cancer screening why is it important? Review data from NLST supporting screening with lowdose CT (LDCT) scanning Discuss the pros and cons of LDCT screening
Lung Cancer Screening
Scan for mobile link. Lung Cancer Screening What is lung cancer screening? Screening examinations are tests performed to find disease before symptoms begin. The goal of screening is to detect disease at
What to know and what to make of it
Lung Cancer Screening: What to know and what to make of it J. Matthew Reinersman, MD Assistant Professor of Surgery Division of Thoracic and Cardiovascular Surgery Department of Surgery University of Oklahoma
Disclosures. Overview. Selection the most accurate statement: Updates in Lung Cancer Screening 5/26/17. No Financial Disclosures
Updates in Lung Cancer Screening Disclosures No Financial Disclosures Neil Trivedi, MD Associate Professor of Clinical Medicine SF VAMC Pulmonary and Critical Care Director, Bronchoscopy & Interventional
New Advances in Lung Cancer
New Advances in Lung Cancer Douglas E. Wood, MD, FACS, FRCSEd (ad hom) Professor and Chief Division of Cardiothoracic Surgery Vice-Chair, Department of Surgery Endowed Chair in Lung Cancer Research University
Screening for Lung Cancer - State of the Art
Screening for Lung Cancer - State of the Art Rohit Kumar, MD Assistant Professor of Medicine Fox Chase Cancer Center Temple University School of Medicine Philadelphia, PA Objectives Review current evidence
Pulmonologist s Perspective
Low-dose CT for lung cancer screening Pulmonologist s Perspective Literature Review Kang-Yun Lee, MD PhD Department of Thoracic Medicine Taipei Medical University- Shuang Ho Hospital Taiwan Local vs. Advanced
CT screening for lung cancer. Should it be done in the Indian context?
CT screening for lung cancer Should it be done in the Indian context? Wilson and Jungner screening criteria 1. The condition sought should be an important health problem. 2. There should be an accepted
Professor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK.
Professor John K Field PhD, FRCPath University of Liverpool Cancer Research Centre, UK. J.K.Field@liv.ac.uk 1.8 million new cases in 2012 Bender Nature Outlook 2014 Probability of survival: ALL participants
DISCLOSURE. Lung Cancer Screening: The End of the Beginning. Learning Objectives. Relevant Financial Relationship(s) Off Label Usage
Peninsula Regional Medical Center 12 th Annual Lung Cancer Conference March 9, 2017 Lung Cancer Screening: The End of the Beginning David E. Midthun M.D. Professor of Medicine College of Medicine, Mayo
Introduction and Background
CT Lung Cancer Screening and the Medical Physicist: Background, Findings and Participant Dosimetry Summary of the National Lung Screening Trial (NLST) Randell Kruger, PhD, DABR Medical Physics Section
Lung Cancer Screening
Lung Cancer Screening Preston Wright, DO University of Kansas School of Medicine- Wichita Family Medicine Residency at Via Christi Hospitals 1 Objectives Identify patients who need screened for lung cancer
Lung Cancer Screening: Benefits and limitations to its Implementation
Lung Cancer Screening: Benefits and limitations to its Implementation Rolando Sanchez, MD Clinical Assistant Professor Pulmonary-Critical Care Medicine University of Iowa Lung cancer - Epidemiology Cancer
The National Lung Screening Trial (NLST)
The National Lung Screening Trial (NLST) Pamela Marcus US National Cancer Institute May 21, 2012 Today s talk NLST: an overview Typical challenges in cancer screening RCTs Starting ti a trial in the presence
CT Screening for Lung Cancer for High Risk Patients
CT Screening for Lung Cancer for High Risk Patients The recently published National Lung Cancer Screening Trial (NLST) showed that low-dose CT screening for lung cancer reduces mortality in high-risk patients
LUNG CANCER SCREENING Anthony C. Campagna, M.D.
LUNG CANCER SCREENING 2012 Anthony C. Campagna, M.D. Attending Physician, Pulmonary and Critical Care Medicine Lahey Clinic, Burlington, MA Assistant Clinical Professor of Medicine Harvard Medical School,
Lung Cancer screening :
Lung Cancer screening : Pro-Contra SAMO interdisciplinary workshop on chest tumors 27 and 28 january 2017 Prof L.P.Nicod Sevice de pneumologie CHUV-Lausanne -CH Lung Cancer How big is the problem? Epidemiology
Example of lung screening
Justification of the use of CT for individual health assessment of asymptomatic people How to obtain evidence for IHA - Example of lung screening Mathias Prokop, MD PhD Professor of Radiology Radboud University
Lung Cancer and CT Screening
Lung Cancer and CT Screening Samer Kanaan, MD February 17 th, 2012 Goals Understand the Societal impact of Lung Cancer Identify Risk Factors for Lung Cancer List Diagnostic Tests Available for Lung Cancer
Lung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer
Lung Cancer Screening Computed Tomography Screening in Pa6ents at Risk for Lung Cancer Doug Arenberg, M.D. University of Michigan Disclosures Objec6ve Define patients who will benefit from screening for
Lung Cancer Screening In High Risk Populations:
Lung Cancer Screening In High Risk Populations: Michael Jaklitsch, M.D. Co-Chair of AATS Task Force on Lung Cancer Screening and Surveillance From the Brigham and Women s Hospital Harvard Medical School.
Screening for Lung Cancer
Screening for Lung Cancer 15 ΜΑΡΤΙΟΥ 2014 Ioannis Gkiozos Pulmonologist Oncology Unit G P General & Chest Diseases Hospital Sotiria Despite advances in therapy, 5-year survival rates of Lung Cancer Remains
Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies. Ashish Sangal, M.D.
Joint Session with ACOFP and Cancer Treatment Centers of America (CTCA): Cancer Screening: Consensus & Controversies Ashish Sangal, M.D. Cancer Screening: Consensus & Controversies Ashish Sangal, MD Director,
6/6/2011. Recruitment methods employed in the. Pamela Marcus, PhD. National Cancer Institute NLST
Recruitment methods employed in the National Lung Screening Trial (NLST) Pamela Marcus, PhD Division of Cancer Prevention National Cancer Institute NLST 1 NLST: The basics Sponsored by the US National
LUNG CANCER SCREENING: LUNG CANCER SCREENING: THE TIME HAS COME LUNG CANCER: A NATIONAL EPIDEMIC
: THE TIME HAS COME Physician Leader, Lung Cancer Multi-Disciplinary Program Fletcher Allen Health Care Annual Meeting Montpelier, VT - April 25, 2014 Gerald S. Davis, MD Professor of Medicine University
LUNG CANCER SCREENING
LUNG CANCER SCREENING Christopher Lettieri MD, FACP, FCCP, FAASM Pulmonary/Critical Care Consultant to the Surgeon General Professor of Medicine Walter Reed National Military Medical Center American College
A Summary from the 2013World Conference on Lung Cancer Sydney, Australia
A Summary from the 2013World Conference on Lung Cancer Sydney, Australia In 2011, the U.S. National Lung Screening Trial (NLST) has demonstrated that low-dose computed tomography (LDCT) screening of high
None
2014 None rosemary clooney Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common
SCREENING FOR EARLY LUNG CANCER. Pang Yong Kek
SCREENING FOR EARLY LUNG CANCER Pang Yong Kek Lecture Outline Why performing screening? How to improve early detection? Benefits and Risks of screening Challenges in screening Conclusion Why Performing
Current Approach to Screening for Lung Cancer. James R Jett M.D.
Current Approach to Screening for Lung Cancer James R Jett M.D. Potential Conflicts of Interest I am Chief Medical Officer for Oncimmune Ltd (Biomarkers of Cancer) Co-Editor of Lung Cancer Section of UP-TO-DATE
Lung Cancer Screening: Now What?
Lung Cancer Screening: Now What? Gerold Bepler, M.D., Ph.D. Director, President & CEO Michigan Cancer Consortium, 2013 Annual Meeting, Lansing, MI, 11/20/13 Lung Cancer #1 Cause of Cancer Death for & *
Learning Objectives. 1. Identify which patients meet criteria for annual lung cancer screening
Disclosure I, Taylor Rowlett, DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context
VHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening
VHA Demonstration Project for Lung Cancer Screening Using Low-Dose Chest CT Screening ATS San Francisco 2016 James K. Brown MD 1, Kathryn L. Rice, MD 2 (1) San Francisco VA (2) Minneapolis VAMC Disclosures
Lung Cancer Screening
Lung Cancer Screening Ravi Salgia, M.D., Ph.D. Professor and Chair Medical Oncology and Therapeutics Research City of Hope Nothing to disclose Disclosure Lung Cancer 2016 >200,000 cases projected >160,000
Lung Cancer Screening
Lung Cancer Screening Steven Leh, MD, FCCP Diplomat of the American Association for Bronchology and Interventional Pulmonology Aurora Medical Group Pulmonary and Sleep Medicine February 10, 2018 Disclosures
LUNG CANCER: LDCT DISCLOSURES NONE. Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, /9/2018
LUNG CANCER: LDCT Erika Swanson, MD Radiation Oncologist Ascension Columbia-St. Mary s February 1, 2018 DISCLOSURES 2 NONE 1 OBJECTIVES 3 Rationale and evidence for LDCT for lung cancer screening Review
LDCT Screening. Steven Kirtland, MD. Virginia Mason Medical Center February 27, 2015
LDCT Screening Steven Kirtland, MD Virginia Mason Medical Center February 27, 2015 2 Disclosures 4 5 Cancer Screening Mrs H 64yo 50 pk year smoker Lung Cancer Epidemiology Leading Cause of Cancer Death
The Maine Lung Cancer Coalition. Working Together to Reduce Lung Cancer in Maine
The Maine Lung Cancer Coalition Working Together to Reduce Lung Cancer in Maine funding Maine Lung Cancer Coalition (MLCC) Webinar Lung Cancer Screening: Following Up On Abnormal Low Dose CT Scans with
10/17/16. Lung Cancer Screening. Question 1: Does lung cancer screening make sense? 3rd lung cancer third most prevalent tumor type
Lung Cancer Screening Greg Rogalski Mercy Radiology Group greg@grogo.org Question 1: Does lung cancer screening make sense? 2 Requirements for successful screening process Sufficiently high prevalence
Lung cancer screening: appropriate pa0ent selec0on and informed decision making
Lung cancer screening: appropriate pa0ent selec0on and informed decision making William C. Black, MD Department of Radiology Norris Co@on Cancer Center Geisel School of Medicine at Dartmouth Dartmouth-
SHARED DECISION MAKING AND LUNG CANCER SCREENING
SHARED DECISION MAKING AND LUNG CANCER SCREENING DISCLOSURES Cathleen E. Morrow, MD None William C. Black, MD No financial disclosure Co-investigator for NLST Member of the ACR Lung-RADS Screening Registry
NC I CCC. A Comprehensive Cancer Center Designated by the National Cancer Institute
NC I CCC A Comprehensive Cancer Center Designated by the National Cancer Institute The Controversy About Lung Cancer Screening David S. Ettinger, M.D., FACP, FCCP Alex Grass Professor of Oncology The Sidney
LUNGS? YOU GET THESE YOUR GUIDE TO YEARLY LUNG CANCER SCREENING CHECKED REGULARLY. WHAT ABOUT YOUR. Think. Screen. Know.
YOU GET THESE CHECKED REGULARLY. WHAT ABOUT YOUR LUNGS? YOUR GUIDE TO YEARLY LUNG CANCER SCREENING WHAT YOU SHOULD KNOW BEFORE, DURING, AND AFTER Think. Screen. Know. Talk to your doctor. TABLE OF CONTENTS
Lung cancer screening in Switzerland
SAMO Interdisciplinary Workshop on Chest Tumors 27 th and 28 th January 2017 Hotel Hermitage, Lucerne Lung cancer screening in Switzerland Walter Weder, MD, Professor of Surgery University Hospital Zurich,
PANEL DISCUSSION: SCREENING FOR LUNG CANCER. Anthony D Weaver MD
PANEL DISCUSSION: SCREENING FOR LUNG CANCER Anthony D Weaver MD Disclosures Anthony Weaver has no relationships to disclose. Thank God! A panel of experts! An Equal Opportunity University Objectives 1.
Mayo Clinic College of Medicine, Rochester, Minnesota, USA
The Oncologist Lung Cancer Commentary: CT Screening for Lung Cancer Caveat Emptor JAMES R. JETT,DAVID E. MIDTHUN Mayo Clinic College of Medicine, Rochester, Minnesota, USA Key Words. CT screening Early
Screening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
Page 1 of 5 Patient Safety: Radiation Dose in X-Ray and CT Exams What are x-rays and what do they do? X-rays are forms of radiant energy, like light or radio waves. Unlike light, x-rays can penetrate the
Ann Intern Med. 2012;156(5):
Lung Cancer Screening Update Doug Arenberg, M.D. University of Michigan Outline Screening; Some simple but necessary truths Do people benefit from screening? What are the harms (and are they outweighed
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES. https://tinyurl.com/hmpn2018
PULMONARY NODULES AND MASSES : DIAGNOSTIC APPROACH AND NEW MANAGEMENT GUIDELINES Heber MacMahon MB, BCh Department of Radiology The University of Chicago https://tinyurl.com/hmpn2018 Disclosures Consultant
Outcomes in the NLST. Health system infrastructure needs to implement screening
Outcomes in the NLST Health system infrastructure needs to implement screening Denise R. Aberle, MD Professor of Radiology and Bioengineering David Geffen School of Medicine at UCLA 1 Disclosures I have
LUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS?
LUNG CANCER SCREENING: ON WHOM DID YOU DO IT AND ON WHOM DO YOU RESPOND TO THE RESULTS? DAVID O. WILSON, MD, MHP DIRECTOR GEORGIA COOPER MEMORIAL LUNG CANCER RESEARCH REGISTRY UNIVERSITY OF PITTSBURGH
National Lung Screening Trial Results
National Lung Screening Trial Results Ella A. Kazerooni, M.D. Professor & Director Cardiothoracic Radiology Associate Chair for Clinical Affairs University of Michigan NLST STOPPED! Lung cancer trial results
Lung Cancer Screening. Eric S. Papierniak, DO NF/SG VHA UF Health
Lung Cancer Screening Eric S. Papierniak, DO NF/SG VHA UF Health Overview Background Supporting evidence Guidelines Practical considerations Patient selection What to do with abnormal results Billing/coding
Estimating Risks from CT Scans - in the Context of CT Scan Benefits
Estimating Risks from CT Scans - in the Context of CT Scan Benefits David J. Brenner Center for Radiological Research Columbia University Medical Center djb3@cumc.columbia.edu There is no question that
Spine MRI and Spine CT Test Request Tip Sheet
Spine MRI and Spine CT MRI is almost always preferred over CT scan; if ordering CT, CLEARLY document why MRI is not appropriate. In cases of back pain without red flags, six weeks of multimodality supervised
Role of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D.
Role of CT in Lung Cancer Screening: 2010 Stuart S. Sagel, M.D. Lung Cancer 219,440 new cases/year in U.S. (2009) 169,390 deaths/year in U.S. mortality greater than from breast, colon, prostate CA combined
GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES
Venice 2017 GUIDELINES FOR PULMONARY NODULE MANAGEMENT : RECENT CHANGES AND UPDATES Heber MacMahon MB, BCh Department of Radiology The University of Chicago Disclosures Consultant for Riverain Medical
Spine MRI and Spine CT Test Request Tip Sheet
Spine MRI and Spine CT With/Without Contrast CT, MRI The study considered best for a specific clinical scenario should be ordered. The second study should be done ONLY if the first study does not provide
Open Access Review Article DOI: /cureus.589. Joshua Dajac 1, Jay Kamdar 1, Austin Moats 2, Brenda Nguyen 1
Open Access Review Article DOI: 10.7759/cureus.589 To Screen or not to Screen: Low Dose Computed Tomography in Comparison to Chest Radiography or Usual Care in Reducing Morbidity and Mortality from Lung
Spine MRI and Spine CT Test Request Tip Sheet
Spine MRI and Spine CT With/Without Contrast CT, MRI The study considered best for a specific clinical scenario should be ordered. The second study should be done ONLY if the first study does not provide
Patti Edwards, Senior Radiographer, West Herts Hospitals, UK. February Radiation Safety
Patti Edwards, Senior Radiographer, West Herts Hospitals, UK. February 2008. Radiation Safety Sub -headings Background Radiation Effects of Radiation Safe Levels Effective Doses ALARA Principle Radiation
Spine MRI and Spine CT Test Request Tip Sheet
Spine MRI and Spine CT With/Without Contrast CT, MRI Studies should NOT be ordered simultaneously as dual studies (i.e., with and without contrast). Radiation exposure is doubled and both views are rarely
Objectives. Why? Why? Background 11/5/ % incurable disease at presentation Locally advanced disease Metastasis. 14% 5 year survival
Objectives Appraise lung cancer screening trials results Review screening guidelines Lung Cancer Screening: Past, Present and Future Chi Wan Koo, MD Koo.chiwan@mayo.edu Discuss recommendations essential
MEDICAL POLICY SUBJECT: LOW-DOSE COMPUTED TOMOGRAPHY (LDCT) FOR LUNG CANCER SCREENING. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: LOW-DOSE COMPUTED CANCER SCREENING 05/18/05, 03/16/06, 12/21/06, 08/16/07, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art
SCBT-MR 2016 Lung Cancer Screening in Practice: State of the Art Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality
Ionizing Radiation Exposure of the Population of the United States. David A. Schauer Executive Director
Ionizing Radiation Exposure of the Population of the United States David A. Schauer Executive Director Key Dates in NCRP s s History 1929: U.S. Advisory Committee on X-ray and Radium Protection 1946: U.S.
Ryan Niederkohr, M.D. Slides are not to be reproduced without permission of author
Ryan Niederkohr, M.D. CMS: PET/CT CPT CODES 78814 Limited Area (e.g., head/neck only; chest only) 78815 78816 Regional (skull base to mid-thighs) True Whole Body (skull vertex to feet) SELECTING FIELD
Faculty Disclosure. Objectives. Lung Cancer in Kentucky: Improving Patient Outcomes 10/28/16. Lung Cancer Burden in Kentucky
Lung Cancer in Kentucky: Improving Patient Outcomes Faculty Disclosure The presenter and members of the development team do not have any conflicts to report. Celeste T. Worth, MCHES Kentucky Collaborative
Published Pulmonary Nodule Guidelines A Synthesis
Published Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj Royal Brompton Hospital London 4/28/2015 1 And very soon to be published Published ^ Pulmonary Nodule Guidelines A Synthesis Dr A Devaraj
Patient Decision Aid. Summary Guide for Clinicians. Clinician s Checklist
U.S. Department of Health & Human Services About Us Careers Contact Us Español FAQ Email Updates Effective Health Care Home / Decision Aids / Lung Cancer Screening Tools Patient Decision Aid Summary Guide
Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017
Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD November 18, 2017 Disclosures I do not have a financial interest/arrangement or affiliation with one or more organizations
I appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
Page 1. Cancer Screening for Women I have no conflicts of interest. Overview. Breast, Colon, and Lung Cancer. Jeffrey A.
Cancer Screening for Women 2017 Breast, Colon, and Lung Cancer Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine University of California, San Francisco I have no conflicts
Relative Survival Rate
5X Su r vi val Th r ou gh Ear l y Det ect i on Cancer Stage I II III IV Relative Survival Rate 55,2% 28% 8% 2% 90% TIME AND COST IS W AITING IN LINE OBJ ECTIVES Reduce Screening Time By Reduce Screening
Original Policy Date
MP 6.01.21 Screening for Lung Cancer Using CT Scanning Medical Policy Section Radiology Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE?
PULMONARY NODULES DETECTED INCIDENTALLY OR BY SCREENING: LOTS OF GUIDELINES BUT WHERE IS THE EVIDENCE? MICHAEL K. GOULD, MD SENIOR RESEARCH SCIENTIST DIRECTOR FOR HEALTH SCIENCES & IMPLEMENTATION SCIENCE
American Cancer Society Lung Cancer Screening Guidelines
American Cancer Society Lung Cancer Screening Guidelines Richard Wender, MD 1 ; Elizabeth T. H. Fontham, MPH, DrPH 2 ; Ermilo Barrera, Jr, MD 3 ; Graham A. Colditz, MD, DrPH 4 ; Timothy R. Church, PhD
Small cell lung cancer (SCLC) is an aggressive malignancy
BRIEF REPORT Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers Sinead Cuffe, MD,* Teng Moua, MD,
Recommendations on Screening for Lung Cancer 2016
Recommendations on Screening for Lung Cancer 2016 Canadian Task Force on Preventive Health Care (CTFPHC) Putting Prevention into Practice Canadian Task Force on Preventive Health Care Groupe d étude canadien
National Jewish Health, the Nation s Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
National Jewish Health, the Nation s Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT Trial to evaluate clinical benefit of EarlyCDT -Lung blood test use in conjunction
Debra Pennington, MD Director of Imaging Dell Children s Medical Center
Debra Pennington, MD Director of Imaging Dell Children s Medical Center 1 Gray (Gy) is 1 J of radiation energy/ 1 kg matter (physical quantity absorbed dose) Diagnostic imaging doses in mgy (.001 Gy)
Selected Controversies. Cancer Screening. Breast Cancer Screening. Selected Controversies. Page 1. Using Best Evidence to Guide Practice
Cancer Screening Using Best Evidence to Guide Practice Judith M.E. Walsh, MD, MH Division of General Internal Medicine Women s Health Center of Excellence University of California, San Francisco Selected
Lung Cancer Screening:
Lung Cancer Screening: Maximizing Gain and Dealing with Pandora s Box Mark M. Fuster, MD Division of Pulmonary & Critical Care UCSD Department of Medicine & VA San Diego Healthcare Service San Diego, CA
Page 1. Selected Controversies. Cancer Screening! Selected Controversies. Breast Cancer Screening. ! Using Best Evidence to Guide Practice!
Cancer Screening!! Using Best Evidence to Guide Practice! Judith M.E. Walsh, MD, MPH! Division of General Internal Medicine! Womenʼs Health Center of Excellence University of California, San Francisco!
Lung Cancer Risk Associated With New Solid Nodules in the National Lung Screening Trial
Cardiopulmonary Imaging Original Research Pinsky et al. Lung Cancer Risk Associated With New Nodules Cardiopulmonary Imaging Original Research Paul F. Pinsky 1 David S. Gierada 2 P. Hrudaya Nath 3 Reginald
Conducting Research Involving Medical Imaging
Conducting Research Involving Medical Imaging J. Keith Smith, MD, PhD Terry Hartman, MPH, MS, CCRC Angela Creighton, MBA April 19, 2018 Objectives Summarize the risks of medical imaging involving ionizing
CT Lung Screening Implementation Challenges: State Based Initiatives
CT Lung Screening Implementation Challenges: State Based Initiatives Andrea McKee, MD Chair Radiation Oncology Lahey Hospital and Medical Center Co-Director Rescue Lung, Rescue Life Program Co-Chair Massachusetts
Early Detection of Lung Cancer. Amsterdam March 5 th 2010
Early Detection of Lung Cancer Amsterdam March 5 th 2010 Rob J van Klaveren, MD, PhD Dept. of Pulmonology Erasmus MC Rotterdam, the Netherlands Early Detection and Screening - Questions to be addressed
Cancer Risks from CT Scans: Now We Have Data What Next?
Cancer Risks from CT Scans: Now We Have Data What Next? David J. Brenner, PhD, DSc Center for Radiological Research Columbia University Medical Center djb3@columbia.edu There is no question that CT has